These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 38734836)
1. Using maximum plasma concentration (C Sun Y; Cheng Y; Hertz DL Cancer Chemother Pharmacol; 2024 Jun; 93(6):525-539. PubMed ID: 38734836 [TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy. Krens SD; McLeod HL; Hertz DL Pharmacogenomics; 2013 Apr; 14(5):555-74. PubMed ID: 23556452 [TBL] [Abstract][Full Text] [Related]
3. Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review. De Iuliis F; Salerno G; Taglieri L; Scarpa S Cancer Chemother Pharmacol; 2015 Oct; 76(4):679-90. PubMed ID: 26198313 [TBL] [Abstract][Full Text] [Related]
6. Oral efficacy and bioavailability of a novel taxane. Polizzi D; Pratesi G; Monestiroli S; Tortoreto M; Zunino F; Bombardelli E; Riva A; Morazzoni P; Colombo T; D'Incalci M; Zucchetti M Clin Cancer Res; 2000 May; 6(5):2070-4. PubMed ID: 10815934 [TBL] [Abstract][Full Text] [Related]
7. Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183. Bröker LE; Valdivieso M; Pilat MJ; Deluca P; Zhou X; Parker S; Giaccone G; Lorusso PM Clin Cancer Res; 2008 Jul; 14(13):4186-91. PubMed ID: 18593998 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Prevention Interventions for Taxane-Induced Dermatologic Adverse Events: A Systematic Review. Marks DH; Qureshi A; Friedman A JAMA Dermatol; 2018 Dec; 154(12):1465-1472. PubMed ID: 30383138 [TBL] [Abstract][Full Text] [Related]
9. Enhanced taxane uptake into bladder tissues following co-administration with either mitomycin C, doxorubicin or gemcitabine: association to exfoliation processes. Pandey R; Jackson JK; Liggins R; Mugabe C; Burt HM BJU Int; 2018 Nov; 122(5):898-908. PubMed ID: 29862643 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study. Kus T; Aktas G; Alpak G; Kalender ME; Sevinc A; Kul S; Temizer M; Camci C Support Care Cancer; 2016 May; 24(5):2085-2091. PubMed ID: 26546457 [TBL] [Abstract][Full Text] [Related]
11. Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology. Chen EI; Crew KD; Trivedi M; Awad D; Maurer M; Kalinsky K; Koller A; Patel P; Kim Kim J; Hershman DL PLoS One; 2015; 10(12):e0145816. PubMed ID: 26710119 [TBL] [Abstract][Full Text] [Related]
13. [Acute typhlitis associated with taxane-based chemotherapy]. Gagliano E; Tonante A; Taranto F; Mamo M; Sturniolo G; Colonese F; Sturniolo G G Chir; 2010; 31(11-12):514-7. PubMed ID: 21232195 [TBL] [Abstract][Full Text] [Related]
14. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975 [TBL] [Abstract][Full Text] [Related]
15. Effect of a Complementary/Integrative Medicine Treatment Program on Taxane-Induced Peripheral Neuropathy: A Brief Report. Ben-Arye E; River Y; Keshet Y; Lavie O; Israeli P; Samuels N Int J Gynecol Cancer; 2018 Jun; 28(5):1045-1049. PubMed ID: 29561303 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis. Shi J; Gao P; Song Y; Chen X; Li Y; Zhang C; Wang H; Wang Z Sci Rep; 2017 Jul; 7(1):5319. PubMed ID: 28706257 [TBL] [Abstract][Full Text] [Related]
17. Recent advances in the new generation taxane anticancer agents. Geney R; Chen J; Ojima I Med Chem; 2005 Mar; 1(2):125-39. PubMed ID: 16787308 [TBL] [Abstract][Full Text] [Related]
18. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies. Wang T; Yu J; Liu M; Chen Y; Zhu C; Lu L; Wang M; Min L; Liu X; Zhang X; Gubat JA; Chen Y Drug Des Devel Ther; 2019; 13():539-553. PubMed ID: 30787595 [TBL] [Abstract][Full Text] [Related]
19. Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer. Kosmas C; Malamos NA; Tsavaris NB; Stamataki M; Stefanou S; Gregoriou A; Rokana S; Vartholomeou M; Antonopoulos MJ J Neurooncol; 2002 Feb; 56(3):265-73. PubMed ID: 12061734 [TBL] [Abstract][Full Text] [Related]
20. The use of vitamin E in preventing taxane-induced peripheral neuropathy. Heiba MA; Ismail SS; Sabry M; Bayoumy WAE; Kamal KA Cancer Chemother Pharmacol; 2021 Dec; 88(6):931-939. PubMed ID: 34468794 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]